ANIX (Anixa Biosciences) Cyclically Adjusted PB Ratio: (As of Sep. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANIX Anixa Biosciences Inc ANIX
32 GF Score
Price $2.74
! 3 Warning Signs
View Full Analysis

What is Anixa Biosciences Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Anixa Biosciences  (NAS:ANIX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Anixa Biosciences Cyclically Adjusted PB Ratio Related Terms


Anixa Biosciences Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Anixa Biosciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anixa Biosciences Cyclically Adjusted PB Ratio Chart

Anixa Biosciences Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.35 13.67 5.82 5.38 6.56

Anixa Biosciences Quarterly Data
Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26 Jul26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.84 6.56 4.83 4.65 0.00

ANIX vs GNLX, PMN, NTHI: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Anixa Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anixa Biosciences Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's Cyclically Adjusted PB Ratio falls into.


ANIX
32GF Score
Anixa Biosciences Inc ANIX
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anixa Biosciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Anixa Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Jul. 2026 is calculated as:

For example, Anixa Biosciences's adjusted Book Value per Share data for the three months ended in Jul. 2026 was:

Adj_Book=Book Value per Share/CPI of Jul. 2026 (Change)*Current CPI (Jul. 2026)
=0.423/333.9180*333.9180
=0.423

Current CPI (Jul. 2026) = 333.9180.

Anixa Biosciences Quarterly Data

Book Value per Share CPI Adj_Book
201610 0.101 241.729 0.140
201701 -0.397 242.839 -0.546
201704 0.307 244.524 0.419
201707 0.363 244.786 0.495
201710 0.477 246.663 0.646
201801 0.387 247.867 0.521
201804 0.360 250.546 0.480
201807 0.338 252.006 0.448
201810 0.287 252.885 0.379
201901 0.281 251.712 0.373
201904 0.327 255.548 0.427
201907 0.288 256.571 0.375
201910 0.257 257.346 0.333
202001 0.261 257.971 0.338
202004 0.246 256.389 0.320
202007 0.364 259.101 0.469
202010 0.361 260.388 0.463
202101 0.520 261.582 0.664
202104 1.196 267.054 1.495
202107 1.218 273.003 1.490
202110 1.179 276.589 1.423
202201 1.127 281.148 1.339
202204 1.067 289.109 1.232
202207 1.034 296.276 1.165
202210 0.940 298.012 1.053
202301 0.899 299.170 1.003
202304 0.866 303.363 0.953
202307 0.823 305.691 0.899
202310 0.781 307.671 0.848
202401 0.775 308.417 0.839
202404 0.738 313.548 0.786
202407 0.677 314.540 0.719
202410 0.621 315.664 0.657
202501 0.554 317.671 0.582
202504 0.499 320.795 0.519
202507 0.506 323.048 0.523
202510 0.459 0.000
202601 0.451 325.252 0.463
202604 0.427 333.020 0.428
202607 0.423 333.918 0.423

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Anixa Biosciences Business Description

Other Exchanges CY71:Germany
Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
32GF Score

Get the complete analysis for ANIX

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.74
Price